Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -39.54% is 54% below its 2-year average of -25.68%, near the low end of its 2-year range (-39.54%–-11.67%).
As of the fiscal period ended Tuesday, June 30, 2026. 24.92% below its 12-month average of -31.66%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -39.54%.
RETURN ON EQUITY (ROE)
-39.54%
RETURN ON EQUITY (ROE) AVG TTM
-31.66%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-24.92%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 650 covered companies
CURRENT VS SECTOR MEDIAN
+1.65%
vs the sector median at left
Bicara Therapeutics Inc. Common Stock
Market Cap
$1.09B
Return on Equity (ROE)
-39.54%
TTM Avg
-31.66%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.09B
Return on Equity (ROE)
-281.14%
TTM Avg
-124.20%
3Y Avg
-84.35%
5Y Avg
-63.72%
Market Cap
$1.09B
Return on Equity (ROE)
22.66%
TTM Avg
22.95%
3Y Avg
21.85%
5Y Avg
17.09%
Market Cap
$1.06B
Return on Equity (ROE)
-63.62%
TTM Avg
-41.08%
3Y Avg
-23.78%
5Y Avg
-22.76%
Market Cap
$1.13B
Return on Equity (ROE)
10.23%
TTM Avg
17.11%
3Y Avg
18.25%
5Y Avg
14.55%
Market Cap
$1.13B
Return on Equity (ROE)
-244.91%
TTM Avg
-17.45%
3Y Avg
-30.16%
5Y Avg
-48.76%
Market Cap
$1.05B
Return on Equity (ROE)
-13.54%
TTM Avg
-40.81%
3Y Avg
-170.75%
5Y Avg
-114.78%
Market Cap
$1.13B
Return on Equity (ROE)
-6.16%
TTM Avg
-10.85%
3Y Avg
-14.08%
5Y Avg
-9.38%
Market Cap
$1.14B
Return on Equity (ROE)
N/A
TTM Avg
35.70%
3Y Avg
35.70%
5Y Avg
35.70%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $1.09B | -39.54% | -31.66% | N/A | N/A |
| Replimune Group, Inc. (REPL)vs › | $1.09B | -281.14% | -124.20% | -84.35% | -63.72% |
| IRadimed Corporation (IRMD)vs › | $1.09B | 22.66% | 22.95% | 21.85% | 17.09% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.06B | -63.62% | -41.08% | -23.78% | -22.76% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 10.23% | 17.11% | 18.25% | 14.55% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | -244.91% | -17.45% | -30.16% | -48.76% |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | -13.54% | -40.81% | -170.75% | -114.78% |
| OPKO Health, Inc. (OPK)vs › | $1.13B | -6.16% | -10.85% | -14.08% | -9.38% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.14B | N/A | 35.70% | 35.70% | 35.70% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.04B | -11.06% | -9.32% | -13.81% | -2.96% |
ROE
-39.5%
ROA
-36.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -39.54% |
| 2026-03-31 | -30.61% |
| 2025-12-31 | -34.36% |
| 2025-09-30 | -30.17% |
| 2025-06-30 | -23.59% |
| 2025-03-31 | -20.12% |
| 2024-12-31 | -13.82% |
| 2024-09-30 | -11.67% |
| 2024-03-31 | -29.17% |
| 2023-12-31 | -23.79% |
